1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsClinical Trial Patient Assistance Program is sponsored by Fibrolamellar Cancer Foundation (FCF). This program provides temporary accommodations near trial sites for Fibrolamellar Carcinoma (FLC) patients with financial need who are enrolled in FCF-supported clinical studies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Research grant program - Fibrolamellar Cancer Foundation Our new AI assistant can help patients, caregivers, and researchers find important information faster. Click the logo in the lower right corner to try it. The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC).
Praveen Sethupathy, PhD, in his lab at Cornell University To apply for a grant, click her e to download the research grant application form. Applicants must be employed by an institution engaged in health-related research. The research must focus specifically on FLC.
Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals.
Because we want our funding to truly make a difference for FLC patients, we want to work closely with researchers to shape proposals and make sure that important efforts can be pursued. We also try to avoid funding redundant efforts or displacing existing funding sources. In addition, collaboration and open sourcing are a requirement for FCF funding, as will be specified in any grant agreement.
The Foundation believes that collaboration and engaging the best talent across institutions, together with early sharing of data and resources, can accelerate the path to a cure for rare cancers like FLC. Applications are reviewed three times annually, with application deadlines of March 1, July 1 and November 1 each year.
The Foundation is also open to time sensitive requests – particularly for truly innovative ideas – throughout the year, with agreement prior to submission. If you need additional information or would like to discuss a proposal concept before completing the application (available above), please contact: Payal Ray, PhD, FCF Research Program Director at pray@fibrofoundation.
org , or Mark Furth, FCF Chief Science Officer at mfurth@fibrofoundation. org . Funded grantees are expected to provide the Foundation with semi-annual financial reports and scientific progress reports for the duration of an approved study.
Please click on the following links to download FCF’s guidelines for the required interim and final reports.
According to the current listing, eligibility includes: FLC patients with financial need participating in FCF-funded clinical trials at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, residing at least 75 miles from the study site. Confirm the full requirements in the official notice before applying.
Clinical Trial Patient Assistance Program is funded by Fibrolamellar Cancer Foundation (FCF). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article